AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%
Agile Therapeutics, Inc.
Agile Therapeutics, Inc. (NASDAQ: AGRX) is a women's healthcare company that aims to satisfy women's unmet medical requirements. Twirla (levonorgestrel and Ethinyl estradiol) transdermal system, the company's initial product, is non-daily prescription contraception. Twirla is based on Skinfusion, a groundbreaking transdermal patch that delivers medication through the skin.
Why Should Investors Make an Exit?
Valuation Methodology: EV/Sales Multiple Based Relative Valuation
(Analysis by Kalkine Group)
* % Premium/(Discount) is based on our assessment of the company's NTM trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.
Stock Recommendation:
AGRX's share price has declined 81.70% in the past nine months and is currently leaning towards the lower band of the 52-week range of USD 0.25 to USD 2.47. We have valued the stock using the EV/Sales-based relative valuation methodology and arrived at a target price of USD 0.24.
Considering the company's highly leveraged balance sheet, lackluster financials, weak liquidity profile, stressed margins, current valuation and associated risks. we recommend a "Sell" rating on the stock at the closing price of USD 0.28, up 1.63% as of March 04, 2022.
Three-Year Technical Price Chart (March 04, 2022). Source: REFINITIV, Analysis by Kalkine Group
* The reference data in this report has been partly sourced from REFINITIV.
* All forecasted figures and industry information have been taken from REFINITIV.